<div id="readability-page-1"><div><p>IN AN interview with private-equity investor David Rubenstein, chief executive officer of Novartis Dr Vasant Narasimhan spoke about the potential and possibilities of pharmaceuticals in a fiercely competitive industry.</p><p>Rubenstein questioned Dr Narasimhan on whether constant drug patent expiry and the need to generate new portfolio of drugs is a good way to make a business. Dr Narasimhan acknowledged the “constant treadmill” and the value of a company’s replacement power, which requires strong research and development capabilities, as well as long-term thinking.</p><p>Few industries in the world are subject to such clockwork-style competitive advantage erosion, where businesses know the exact year in which generic drug sales will erode their revenues.</p></div></div>

諾華制藥

<p>諾華製藥首席執行官 Vasant Narasimhan 博士討論了製藥行業面臨的挑戰和潛力，強調了強大研發和長期思維的重要性。他承認藥物專利到期的持續壓力以及對新藥組合的需求，突出了行業獨特競爭優勢的侵蝕</p>

新加坡的生物技術戰略將從集體合作而非競爭中獲益